In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. Nials AT et al. J Pharmacol Exp Ther. 2011 Apr;337(1):137-44.
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Singh D et al. Respir Res. 2010 Mar 1;11:26.
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.